Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06570213 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD
A Early Phase 1 study, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 270
- Enrollment target
NCT06570213 is a Early Phase 1 study that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 270 participants.
The verdict
NCT06570213, a Early Phase 1 study, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain. The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.
Interventions
- BEHAVIORAL Cognitive Processing Therapy
- DRUG Stellate Ganglion Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06570213
The ClinicalTrials.gov registry entry for NCT06570213 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cognitive Processing Therapy is the first listed.
NCT06570213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06570213 about?
NCT06570213 is a clinical study titled "Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD". The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk...
What is the current status of trial NCT06570213?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 270 participants. The study started on 2026-04-01. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT06570213?
The interventions under investigation include: Cognitive Processing Therapy (BEHAVIORAL), Stellate Ganglion Block (DRUG).
Who is sponsoring clinical trial NCT06570213?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.